DE602007006492D1 - Derivatisierung des granulozytenkoloniestimulierenden faktors - Google Patents

Derivatisierung des granulozytenkoloniestimulierenden faktors

Info

Publication number
DE602007006492D1
DE602007006492D1 DE602007006492T DE602007006492T DE602007006492D1 DE 602007006492 D1 DE602007006492 D1 DE 602007006492D1 DE 602007006492 T DE602007006492 T DE 602007006492T DE 602007006492 T DE602007006492 T DE 602007006492T DE 602007006492 D1 DE602007006492 D1 DE 602007006492D1
Authority
DE
Germany
Prior art keywords
coloniestimulating
derivatisation
granulocyte
factor
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007006492T
Other languages
German (de)
English (en)
Inventor
Sanjay Jain
Peter Laing
Gregory Gregoriadis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipoxen Technologies Ltd
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Publication of DE602007006492D1 publication Critical patent/DE602007006492D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
DE602007006492T 2006-07-25 2007-07-25 Derivatisierung des granulozytenkoloniestimulierenden faktors Active DE602007006492D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117830 2006-07-25
PCT/GB2007/002816 WO2008012525A1 (en) 2006-07-25 2007-07-25 Derivatisation of granulocyte colony-stimulating factor

Publications (1)

Publication Number Publication Date
DE602007006492D1 true DE602007006492D1 (de) 2010-06-24

Family

ID=37397314

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007006492T Active DE602007006492D1 (de) 2006-07-25 2007-07-25 Derivatisierung des granulozytenkoloniestimulierenden faktors

Country Status (10)

Country Link
US (22) US10300144B2 (enExample)
EP (6) EP2043616B1 (enExample)
JP (14) JP2009544680A (enExample)
KR (1) KR101400105B1 (enExample)
CN (2) CN101511391B (enExample)
AT (1) ATE467642T1 (enExample)
DE (1) DE602007006492D1 (enExample)
ES (5) ES2581902T3 (enExample)
RU (1) RU2432175C2 (enExample)
WO (4) WO2008012525A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
WO2005016973A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Polysialic acid derivatives
JP2009544680A (ja) 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
JP5876208B2 (ja) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
EP2409995A3 (en) 2007-02-28 2012-08-15 Lipoxen Technologies Limited Reduction of endotoxin in polysialic acids
AU2008290217B2 (en) 2007-08-20 2013-09-05 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
RU2391354C1 (ru) * 2008-10-15 2010-06-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН, Российская Федерация, от имени которой выступает Федеральное агентство по науке и инновациям Комплекс биологически активного рекомбинантного белка с полисиаловой кислотой
US8586710B2 (en) * 2008-10-20 2013-11-19 Usv, Ltd. Process for gram scale production of PEG-r-metHuG-CSF
AU2009308909A1 (en) * 2008-10-31 2010-05-06 Amgen Inc. Materials and methods relating to stem cell mobilization by multi-PEGylated granulocyte colony stimulating factor
SG173117A1 (en) 2009-01-28 2011-08-29 Smartcells Inc Crystalline insulin-conjugates
SG193837A1 (en) 2009-01-28 2013-10-30 Smartcells Inc Conjugate based systems for controlled drug delivery
WO2010088268A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND ITS USE
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3093029A1 (en) * 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
JP5909755B2 (ja) * 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CN101787117B (zh) * 2010-02-08 2012-05-23 江南大学 聚乙二醇-聚唾液酸嵌段共聚物的制备方法及应用
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
WO2011156242A2 (en) * 2010-06-11 2011-12-15 Lpath, Inc. Improved anti-lysophospholipid antibody design using antibody structures
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
AU2011282987A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
CA2805739A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
BR112013018516B1 (pt) 2011-01-20 2023-11-07 Protalix Ltd Construto de expressão de ácido nucleico, método de produção de uma proteína alfa-galactosidase humana recombinante, proteína alfagalactosidase humana, composição farmacêutica, e, uso de uma proteína alfagalactosidase humana ou de uma composição
CN104220086A (zh) 2011-11-17 2014-12-17 塞比克斯股份公司 Peg化的c-肽
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
JP2019218265A (ja) * 2016-09-14 2019-12-26 生化学工業株式会社 ペプチドの血中滞留性を増強させる方法
US20190083636A1 (en) * 2017-04-25 2019-03-21 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
WO2018197545A1 (en) * 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating multiple myeloma cancers expressing high levels of epo-receptor using psa-epo
WO2020099513A1 (en) * 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
JP2022519586A (ja) * 2019-02-04 2022-03-24 ゼネティック バイオサイエンシーズ インコーポレイテッド 糖ポリシアル酸化治療用タンパク質を使用する方法
CA3145382A1 (en) 2019-07-08 2021-01-14 Gi Innovation, Inc. Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of ige fc receptor, and pharmaceutical composition comprising same
WO2022033480A1 (zh) * 2020-08-11 2022-02-17 隆延生物科技（上海）有限公司 一种液体制剂及其应用
CN114966021B (zh) * 2022-05-19 2025-03-04 山东博科生物产业有限公司 一种稳定的脂蛋白相关磷脂酶a2测定试剂盒

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2930542A1 (de) 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
US5308617A (en) * 1988-08-10 1994-05-03 Halzyme Ltd. Protein heparin conjugates
US7217689B1 (en) * 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
KR100221066B1 (ko) * 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
EP0550108B1 (en) 1991-12-30 1998-03-18 Akzo Nobel N.V. Sustained release thyroactive composition
JP2747967B2 (ja) * 1993-07-23 1998-05-06 雪印乳業株式会社 シアル酸粉末
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2299548C (en) * 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death
WO1999043307A1 (en) 1998-02-26 1999-09-02 Prange Arthur J Jr Thyroid hormone replacement using sustained release triiodothyronine
RU2141531C1 (ru) 1999-05-26 1999-11-20 Российское акционерное общество открытого типа "Биопрепарат" Способ получения рекомбинантного инсулина человека
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
DE60116137T2 (de) 2000-05-16 2006-08-24 Lipoxen Technologies Ltd. Derivatisierung von proteinen in wässrigem lösungsmittel
WO2001087272A2 (en) 2000-05-18 2001-11-22 Therics, Inc. Encapsulating a toxic core within a non-toxic region in an oral dosage form
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
JP5170931B2 (ja) * 2000-10-16 2013-03-27 中外製薬株式会社 Ｐｅｇ修飾エリスロポエチン
CA2431964C (en) * 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
KR100401296B1 (ko) 2000-12-27 2003-10-11 드림바이오젠 주식회사 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법
ES2411007T3 (es) * 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
AU2002351746A1 (en) 2001-12-21 2003-07-15 Maxygen Aps Erythropoietin conjugates
ITPD20010302A1 (it) 2001-12-28 2003-06-28 Bbs Riva Spa Dispositivo idraulico per pompare e / p intercettare metallo allo stato fuso
US6763226B1 (en) 2002-07-31 2004-07-13 Computer Science Central, Inc. Multifunctional world wide walkie talkie, a tri-frequency cellular-satellite wireless instant messenger computer and network for establishing global wireless volp quality of service (qos) communications, unified messaging, and video conferencing via the internet
EP1400533A1 (en) * 2002-09-11 2004-03-24 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
AU2003255406B2 (en) * 2002-09-11 2009-09-10 Fresenius Kabi Deutschland Gmbh Hydroxyalkyl starch derivatives
BRPI0409322B8 (pt) 2003-04-11 2021-05-25 Antriabio Inc método para preparar um conjugado de insulina-polímero
WO2004101619A1 (ja) 2003-05-15 2004-11-25 Shionogi Co., Ltd. 機能的糖ペプチドの合理的設計および合成
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
WO2005003149A1 (en) 2003-07-03 2005-01-13 Cipla Limited Process for the preparation of finasteride form i
ATE345995T1 (de) 2003-08-05 2006-12-15 Dematic Corp Querantrieb für motorisierte rolle
CA2948114C (en) 2003-08-06 2019-02-26 Che-Hung Robert Lee Polysaccharide-protein conjugate vaccines
WO2005014050A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and g-csf
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
WO2005016973A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Polysialic acid derivatives
JP4719686B2 (ja) * 2003-11-24 2011-07-06 バイオジェネリックス アーゲー ＧｌｙｃｏＰＥＧ化エリスロポエチン
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
BRPI0417342A (pt) 2003-12-03 2007-04-17 Neose Technologies Inc fator estimulante de colÈnia de granulócitos glicopeguilado
SG151261A1 (en) * 2004-03-11 2009-04-30 Fresenius Kabi De Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
FR2868071B1 (fr) * 2004-03-26 2006-06-09 Biomerieux Sa Reactifs de marquage, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques
DE102004030392A1 (de) 2004-06-23 2006-01-19 Endress + Hauser Flowtec Ag, Reinach Meßwandler vom Vibrationstyp
WO2006014148A2 (fr) 2004-08-04 2006-02-09 Sergey Alexandrovich Orlov Procede permettant d'organiser un processus de jeu a action intermittente
GB2416993A (en) 2004-08-11 2006-02-15 Dinesh Verma Opthalmic prosthesis
US7875708B2 (en) 2004-08-12 2011-01-25 Lipoxen Technologies Limited Sialic acid derivatives
ES2640767T3 (es) 2004-08-12 2017-11-06 Lipoxen Technologies Limited Fraccionamientodepolisacáridos cargados
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
EP1853634B1 (en) 2005-02-23 2016-08-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
JP3989936B2 (ja) * 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
WO2007047997A2 (en) * 2005-10-19 2007-04-26 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
JP2009544680A (ja) * 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
CN102470144A (zh) 2009-07-16 2012-05-23 花王株式会社 进食后血中胰岛素浓度上升抑制剂
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質

Also Published As

Publication number Publication date
CN101511391A (zh) 2009-08-19
KR20090057370A (ko) 2009-06-05
US20160129123A1 (en) 2016-05-12
ES2647528T3 (es) 2017-12-22
JP2013121982A (ja) 2013-06-20
US20170119893A1 (en) 2017-05-04
US20130116176A1 (en) 2013-05-09
JP6243456B2 (ja) 2017-12-06
US8933026B2 (en) 2015-01-13
WO2008012542A8 (en) 2009-07-16
JP2015145400A (ja) 2015-08-13
EP2630972A3 (en) 2013-10-16
EP2630972B1 (en) 2017-08-30
WO2008012542A3 (en) 2008-05-15
KR101400105B1 (ko) 2014-06-19
US20100016217A1 (en) 2010-01-21
US20160095930A1 (en) 2016-04-07
WO2008012528A1 (en) 2008-01-31
JP2009544680A (ja) 2009-12-17
ES2581902T3 (es) 2016-09-08
CN101511391B (zh) 2013-03-13
JP2013049675A (ja) 2013-03-14
ATE467642T1 (de) 2010-05-15
US8299015B2 (en) 2012-10-30
US9474805B2 (en) 2016-10-25
ES2569066T3 (es) 2016-05-06
WO2008012540A1 (en) 2008-01-31
US20170058273A1 (en) 2017-03-02
WO2008012525A8 (en) 2010-04-29
US20140161765A1 (en) 2014-06-12
US9492557B2 (en) 2016-11-15
US9234020B2 (en) 2016-01-12
JP5096466B2 (ja) 2012-12-12
JP2009544681A (ja) 2009-12-17
US20150158924A1 (en) 2015-06-11
WO2008012540A9 (en) 2009-03-12
US8299026B2 (en) 2012-10-30
US20220133898A1 (en) 2022-05-05
JP5586669B2 (ja) 2014-09-10
US9492556B2 (en) 2016-11-15
RU2009105696A (ru) 2010-08-27
US20180289823A1 (en) 2018-10-11
EP2043692B1 (en) 2016-05-18
JP2009544678A (ja) 2009-12-17
EP2043693A1 (en) 2009-04-08
EP2041167A1 (en) 2009-04-01
US20190216938A1 (en) 2019-07-18
US8394921B2 (en) 2013-03-12
JP6581157B2 (ja) 2019-09-25
JP2016128493A (ja) 2016-07-14
JP2015007062A (ja) 2015-01-15
JP2018039791A (ja) 2018-03-15
JP5419689B2 (ja) 2014-02-19
US20100056427A1 (en) 2010-03-04
JP6055506B2 (ja) 2016-12-27
US8981050B2 (en) 2015-03-17
US8796207B2 (en) 2014-08-05
JP6165079B2 (ja) 2017-07-19
EP3299033A1 (en) 2018-03-28
US20160129124A1 (en) 2016-05-12
RU2432175C2 (ru) 2011-10-27
US20150252090A1 (en) 2015-09-10
JP2013241446A (ja) 2013-12-05
US10300144B2 (en) 2019-05-28
US20140134147A1 (en) 2014-05-15
US20140315802A1 (en) 2014-10-23
CN103169984A (zh) 2013-06-26
JP5941440B2 (ja) 2016-06-29
WO2008012525A1 (en) 2008-01-31
JP6203342B2 (ja) 2017-09-27
ES2581983T3 (es) 2016-09-08
JP5912152B2 (ja) 2016-04-27
EP2041167B1 (en) 2010-05-12
JP5542195B2 (ja) 2014-07-09
JP2017018107A (ja) 2017-01-26
CN103169984B (zh) 2016-08-03
JP2014114315A (ja) 2014-06-26
JP5420091B2 (ja) 2014-02-19
EP2043692A2 (en) 2009-04-08
US20140309166A1 (en) 2014-10-16
US20140309407A1 (en) 2014-10-16
EP2043616B1 (en) 2016-01-27
EP2630972A2 (en) 2013-08-28
US8946406B2 (en) 2015-02-03
ES2344670T3 (es) 2010-09-02
EP2043616A1 (en) 2009-04-08
WO2008012542A2 (en) 2008-01-31
US20170080054A1 (en) 2017-03-23
US9579393B2 (en) 2017-02-28
US9789163B2 (en) 2017-10-17
JP2013100309A (ja) 2013-05-23
US20150147307A1 (en) 2015-05-28
JP2009544677A (ja) 2009-12-17
US20100022441A1 (en) 2010-01-28
US20100022443A1 (en) 2010-01-28
US9266936B2 (en) 2016-02-23
US9549990B2 (en) 2017-01-24
EP2043693B1 (en) 2016-04-27
US9040478B2 (en) 2015-05-26

Similar Documents

Publication Publication Date Title
DE602007006492D1 (de) Derivatisierung des granulozytenkoloniestimulierenden faktors
NO20083948L (no) Glykosylerte antistoffer
CL2011000205A1 (es) Composicion biocida que comprende ciprodinil y boscalid; metodo para controlar enfermedades, en plantas utiles o en material de propagacion, causadas por fitopatogenos (div. sol. n°2602-06).
WO2005113606A3 (en) Fgf-21 fusion proteins
UA94221C2 (en) Lipocalin protein
EP2360170A3 (en) Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
WO2006133089A3 (en) Improved human interferon molecules and their uses
WO2007060117A3 (de) Chimäre keratinbindende effektorproteine
CA2597065C (en) Compositions and methods related to soluble g-protein coupled receptors (sgpcrs)
IL188611A0 (en) Sp1 polypeptides, modified sp1 polypeptides and uses thereof
IL189258A0 (en) Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
BRPI0602365A8 (pt) Dispositivo de comunicação
MX2008004734A (es) Composicion rica en leucina.
MX341064B (es) Variantes de la familia il-1.
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
TW200724159A (en) Stable emulsion composition
PL1922128T3 (pl) Element do zmniejszania zawartości drobnego pyłu w powietrzu, za pomocą mchów i/lub porostów
WO2006106348A3 (en) Protein glycosylation
DE602006011275D1 (de) Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat
HRP20110093T4 (hr) Kristalna baza escitaloprama i orodisperzibilne tablete koje sadrže bazu escitaloprama
ATE320474T1 (de) Transparentes wässriges beschichtungsmittel mit glasmehl
MX2007007355A (es) 5-(2,2-dimetil-ciclopropil)-3-metil-pen-2-en nitrilo como fragancia y sabor.
GEP20084546B (en) Novel association consisting of an anti-atherothrombotic agent and of platelet antiaggregating agent
EP1702803A3 (de) Strukturbauteil, insbesondere Abschirmteil

Legal Events

Date Code Title Description
8364 No opposition during term of opposition